Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

ADILW
Adial Pharmaceuticals, Inc Warrant
stock NASDAQ

Inactive
Jul 27, 2023
0.000900USD-57.143%(-0.001200)5,182
Pre-market
Dec 31, 1969 7:00:00 PM EST
0.00USD-100.000%(0.00)0
After-hours
Dec 31, 1969 7:00:00 PM EST
0.00USD0.000%(0.00)0
OverviewHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 24, 2022
09:25AM EST  Adial Pharmaceuticals Receives Notice of Allowance on U.S. Patent   GlobeNewswire Inc
Jan 10, 2022
09:04AM EST  Adial Pharmaceuticals to Present at the H.C. Wainwright BioConnect   GlobeNewswire Inc
Dec 22, 2021
09:25AM EST  Adial Pharmaceuticals Completes Private Placement of Common Stock   GlobeNewswire Inc
Dec 8, 2021
09:25AM EST  Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the appointment of Cary J. Claiborne as Chief Operating Officer. Mr. Claiborne will continue to serve on the Board of Directors.   GlobeNewswire Inc
Nov 29, 2021
09:00AM EST  Adial Pharmaceuticals Announces Positive Pre-Clinical Data for   GlobeNewswire Inc
Nov 17, 2021
09:43AM EST  REMINDER: Adial Pharmaceuticals to Host Conference Call Thursday,   GlobeNewswire Inc
Nov 10, 2021
09:26AM EST  Adial Pharmaceuticals Announces Private Placement of Common Stock   GlobeNewswire Inc
Nov 9, 2021
09:15AM EST  Adial Pharmaceuticals Schedules Conference Call to Provide   GlobeNewswire Inc
Nov 3, 2021
09:10AM EDT  Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the appointment of Cary J. Claiborne to the Board of Directors, increasing the number of board members to seven.   GlobeNewswire Inc
Oct 21, 2021
10:14AM EDT  Results suggest potential of PNV-5030 as both a standalone and combination therapyto reduce or eliminate opioid use and achieve meaningful pain reduction   GlobeNewswire Inc
Oct 18, 2021
09:30AM EDT  Adial Pharmaceuticals to Present at Dawson James Securities 6th   GlobeNewswire Inc
Sep 30, 2021
09:25AM EDT  Adial Pharmaceuticals Announces Greater Than 50% of Patients   GlobeNewswire Inc
Sep 28, 2021
09:49AM EDT  Adial Pharmaceuticals Announces Research Collaboration Agreement   GlobeNewswire Inc
Sep 15, 2021
10:08AM EDT  Adial CEO William Stilley Invited to Participate in Maxim   GlobeNewswire Inc
Sep 7, 2021
09:00AM EDT  Adial Pharmaceuticals to Present at the H.C. Wainwright 23rd   GlobeNewswire Inc
Aug 31, 2021
09:30AM EDT  Adial Pharmaceuticals Exceeds Enrollment Target in   GlobeNewswire Inc
Aug 20, 2021
10:45AM EDT  Adial Pharmaceuticals Reaches Full Enrollment Target for   GlobeNewswire Inc
09:40AM EDT  Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (Adial or the Company), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, will host a conference call at 11:00 A.M. Eastern Time today, August 20, 2021 to provide a clinical update and discuss the latest business developments.   GlobeNewswire Inc
Aug 12, 2021
02:50PM EDT  Adial Pharmaceuticals Schedules Conference Call to Provide   GlobeNewswire Inc
Aug 10, 2021
09:30AM EDT  Adial Pharmaceuticals Awarded U.S. and International Patents for   GlobeNewswire Inc
Jul 14, 2021
02:00PM EDT  Data merits further testing for pain reduction as a possible alternative to opioids   GlobeNewswire Inc
Jul 7, 2021
10:12AM EDT  Adial Announces $5,000,000Above Market Private   GlobeNewswire Inc
Jul 6, 2021
09:25AM EDT  The Phase 3 ONWARD Trial Meets its Screening   GlobeNewswire Inc
Jun 28, 2021
09:45AM EDT  Adial Joins Russell Microcap Index   GlobeNewswire Inc
Jun 24, 2021
05:08PM EDT  Adial Pharmaceuticals Provides Regulatory and Development Update   GlobeNewswire Inc
Jun 22, 2021
09:56AM EDT  Adial Pharmaceuticals Plans to Enter Genetic Testing Market   GlobeNewswire Inc
Jun 7, 2021
09:30AM EDT  Adial Pharmaceuticals Comments on Article in The   GlobeNewswire Inc
Jun 3, 2021
09:55AM EDT  Adial Announces Funding of Management-Led $2,100,000 Above Market   GlobeNewswire Inc
May 18, 2021
01:19PM EDT  Adial Pharmaceuticals Featured on Multiple News Broadcasts   GlobeNewswire Inc
Mar 17, 2021
10:00AM EDT  Adial Founder and Chief Medical Officer Dr. Bankole   GlobeNewswire Inc
Mar 15, 2021
09:30AM EDT  Adial Announces Management-Led $2,100,000Above Market   GlobeNewswire Inc
Feb 26, 2021
03:06PM EST  Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (Adial), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that it will host a Town Hall at 1 P.M., Eastern Time on Thursday, March 18, 2021.   GlobeNewswire Inc
11:20AM EST  Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (Adial or the Company), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced the exercise of 712,500 warrants from its June 2020 financing for net proceeds to the company of $1,425,000.   GlobeNewswire Inc
Feb 25, 2021
09:30AM EST  Adial Pharmaceuticals Achieves 50% Enrollment in   GlobeNewswire Inc
Feb 23, 2021
01:00PM EST  Adial to File Fast Track Application for AD04 with the FDA   GlobeNewswire Inc
Oct 22, 2020
09:30AM EDT  Todos Medical Announces Distribution Agreement with Adial   GlobeNewswire Inc
08:30AM EDT  Avalon GloboCare and Adial Pharmaceuticals Announce Strategic   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC